Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ: CPIX · Real-Time Price · USD
4.280
-0.080 (-1.83%)
Apr 2, 2025, 4:00 PM EDT - Market closed
CPIX Revenue
In the year 2024, Cumberland Pharmaceuticals had annual revenue of $37.87M, down -4.26%. Cumberland Pharmaceuticals had revenue of $10.44M in the quarter ending December 31, 2024, with 11.57% growth.
Revenue (ttm)
$37.87M
Revenue Growth
-4.26%
P/S Ratio
1.62
Revenue / Employee
$416,131
Employees
91
Market Cap
59.78M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 37.87M | -1.68M | -4.26% |
Dec 31, 2023 | 39.55M | -2.46M | -5.85% |
Dec 31, 2022 | 42.01M | 6.03M | 16.75% |
Dec 31, 2021 | 35.99M | -1.46M | -3.89% |
Dec 31, 2020 | 37.44M | 3.05M | 8.88% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CPIX News
- 14 days ago - FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference - PRNewsWire
- 4 weeks ago - Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth - PRNewsWire
- 5 weeks ago - CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS - PRNewsWire
- 6 weeks ago - VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA - PRNewsWire
- 2 months ago - Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease - Benzinga
- 2 months ago - Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease - PRNewsWire
- 4 months ago - Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday? - Benzinga